Literature DB >> 21596678

Men who have sex with men, risk behavior, and HIV infection: integrative analysis of clinical, epidemiological, and laboratory databases.

Itzchak Levy1, Zohar Mor, Emilia Anis, Shlomo Maayan, Eyal Leshem, Shimon Pollack, Michal Chowers, Orna Mor, Klaris Riesenberg, Zev Sthoeger, Daniela Ram, Zehava Grossman.   

Abstract

BACKGROUND: Centralized data collection and analytic tools facilitate tracing HIV transmission trends at the patient-population level with increasing resolution, complementing behavioral studies while avoiding sampling biases. By several measures, the rate of HIV infection among men who have sex with men (MSM) in Israel increased in the past several years more rapidly than was expected. We describe features of the data that connect this increase to behavioral changes.
METHODS: We retrospectively analyzed data from the national HIV reference laboratory and the national HIV and sexually transmitted infections registries. We examined changes in selected epidemiologic and clinical parameters and in the pattern of drug-resistant virus transmission among MSM in Israel. In particular, virus isolates from 296 MSM (23.8% of all MSM who received a diagnosis) were genotyped, drug-resistance conferring mutations were characterized, and phylogenetic trees were constructed.
RESULTS: Compared with earlier years, during 2007-2009 MSM were more often infected with drug-resistant virus before treatment initiation, were coinfected with syphilis, and received a diagnosis during acute retroviral syndrome. Phylogenetic analysis suggested frequent transmission of drug-resistant HIV by drug-treated individuals to >1 partner. Secondary transmission of resistant virus by drug-naive patients is also consistent with the phylogenetic patterns. In addition, non-B HIV subtypes began to appear among MSM.
CONCLUSIONS: Together, our findings suggest that the sexual behavior of MSM, both HIV-infected and uninfected, has become riskier, contributing to the number of those seeking early clarification of status, to syphilis comorbidity, and to the spread of drug resistance. These findings call for action by public health planners and community-based organizations aimed at increasing awareness of the risks, bringing a change in attitude and establishing safe sex norms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596678     DOI: 10.1093/cid/cir244

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  The HIV epidemic among men who have sex with men--behaviour beats science.

Authors:  Zohar Mor; Michael Dan
Journal:  EMBO Rep       Date:  2012-10-16       Impact factor: 8.807

2.  Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.

Authors:  Seble G Kassaye; Zehava Grossman; Maya Balamane; Betsy Johnston-White; Chenglong Liu; Princy Kumar; Mary Young; Michael C Sneller; Irini Sereti; Robin Dewar; Catherine Rehm; William Meyer; Robert Shafer; David Katzenstein; Frank Maldarelli
Journal:  Clin Infect Dis       Date:  2016-06-15       Impact factor: 9.079

Review 3.  Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions.

Authors:  Bluma Brenner; Mark A Wainberg; Michel Roger
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

4.  Future of phylogeny in HIV prevention.

Authors:  Bluma G Brenner; Mark A Wainberg
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

5.  Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project): Phylogenetics Identify HIV-1-Infected Individuals With Social Links.

Authors:  Evangelia-Georgia Kostaki; Georgios K Nikolopoulos; Eirini Pavlitina; Leslie Williams; Gkikas Magiorkinis; John Schneider; Britt Skaathun; Ethan Morgan; Mina Psichogiou; Georgios L Daikos; Vana Sypsa; Pavlo Smyrnov; Ania Korobchuk; Meni Malliori; Angelos Hatzakis; Samuel R Friedman; Dimitrios Paraskevis
Journal:  J Infect Dis       Date:  2018-07-24       Impact factor: 5.226

6.  Thirty years of HIV in Israel: current epidemiology and future challenges.

Authors:  Zohar Mor; Ruth Weinstein; Itamar Grotto; Yana Levin; Daniel Chemtob
Journal:  BMJ Open       Date:  2013-07-06       Impact factor: 2.692

7.  Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.

Authors:  Roy Moscona; Daniela Ram; Marina Wax; Efrat Bucris; Itzchak Levy; Ella Mendelson; Orna Mor
Journal:  J Int AIDS Soc       Date:  2017-08-10       Impact factor: 5.396

8.  Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.

Authors:  Boaz Avidor; Dan Turner; Zohar Mor; Shirley Chalom; Klaris Riesenberg; Eduardo Shahar; Shimon Pollack; Daniel Elbirt; Zev Sthoeger; Shlomo Maayan; Karen Olshtain-Pops; Diana Averbuch; Michal Chowers; Valery Istomin; Emilia Anis; Ella Mendelson; Daniela Ram; Itzchak Levy; Zehava Grossman
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  A Population-Structured HIV Epidemic in Israel: Roles of Risk and Ethnicity.

Authors:  Zehava Grossman; Boaz Avidor; Zohar Mor; Michal Chowers; Itzchak Levy; Eduardo Shahar; Klaris Riesenberg; Zev Sthoeger; Shlomo Maayan; Wei Shao; Margalit Lorber; Karen Olstein-Pops; Daniel Elbirt; Hila Elinav; Ilan Asher; Diana Averbuch; Valery Istomin; Bat Sheva Gottesman; Eynat Kedem; Shirley Girshengorn; Zipi Kra-Oz; Yonat Shemer Avni; Sara Radian Sade; Dan Turner; Frank Maldarelli
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

10.  Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes.

Authors:  Zehava Grossman; Jonathan M Schapiro; Itzchak Levy; Daniel Elbirt; Michal Chowers; Klaris Riesenberg; Karen Olstein-Pops; Eduardo Shahar; Valery Istomin; Ilan Asher; Bat-Sheva Gottessman; Yonat Shemer; Hila Elinav; Gamal Hassoun; Shira Rosenberg; Diana Averbuch; Keren Machleb-Guri; Zipi Kra-Oz; Sara Radian-Sade; Hagit Rudich; Daniela Ram; Shlomo Maayan; Nancy Agmon-Levin; Zev Sthoeger
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.